← brief for 2026-10-23 · Slowing decline

GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.

Paper A Peer reviewed Meta-analysis or large trial

Key takeaways

This review looked at GLP-1 drugs, which are often used for diabetes. It found that these drugs lower the risk of major heart events. The risk dropped by 12% to 26% in people with type 2 diabetes. The review also notes benefits for the heart and kidneys. This is based on large, well-known clinical trials.

Who did this work

Jang R · Jang M · Ruan X · Jin C · Kim W

Source

Paper · PubMed, the drug frontier · 2026 Oct 23
https://pubmed.ncbi.nlm.nih.gov/42918905/